Bioequivalence evaluation of two marketed brands of stavudine 40 mg capsules in healthy human South African volunteers.
Stavudine (d4T), a thymidine nucleoside analogue has been effectively used for treatment of patients infected with HIV. A randomized, two-way, crossover study was conducted in 24 fasting, healthy, Caucasian male volunteers to compare plasma pharmacokinetic (PK) profile and single-dose tolerability of a new d4T formulation (Stavir, Cipla Ltd, India; 40 mg capsule, test, T) with that of reference (R) formulation (Zerit), Bristol-Myers Squib, NJ, USA; capsule, 40 mg). Each volunteer received T and R formulation separated by at least 10 days of drug free wash-out period. Plasma concentrations of d4T, determined upto 24h post-dose by a validated LC-MS/MS assay were utilized to assess PK parameters such as maximum observed plasma concentration (Cmax), time to Cmax (tmax), and area under plasma concentration curve (AUC(infinity)). The primary plasma PK parameters, Cmax, and AUC(infinity), of anti-retroviral were comparable for either of the formulations. tmax was achieved within an hour suggesting rapid absorption of d4T from both formulations. Geometric mean ratios (GMR) (percentage reference) of AUC(infinity) and Cmax, and their 90% confidence intervals (CI) were 106.32 [102.52-110.26] and 102.32 [90.25-116.00], respectively. As the 90% CI of GMR were entirely within 80-125% for log-transformed parameters, two formulations were considered bioequivalent, in the extent and rate of absorption. Both formulations exhibited similar tolerability under fasting conditions.
Narang
Vishal S
VS
Department of Clinical Research, Cipla Ltd, Mumbai 400008, India.
Lulla
Amar
A
Malhotra
Geena
G
Purandare
Shrinivas
S
D000328:Adult; D000704:Analysis of Variance; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D006801:Humans; D008297:Male; D013019:South Africa; D018119:Stavudine / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
D002214:Capsules; D018119:Stavudine